New Zealand markets open in 6 hours 7 minutes

Endonovo Therapeutics, Inc. (ENDV)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0014+0.0000 (+3.70%)
As of 03:50PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.0014
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0010 - 0.0014
52-week range0.0010 - 0.0178
Avg. volume1,360,283
Market cap489,151
Beta (5Y monthly)-0.31
PE ratio (TTM)0.14
EPS (TTM)0.0100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc

    Los Angeles, CA, March 28, 2024 (GLOBE NEWSWIRE) -- Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement (APA), originally signed in December 2023, for the acquisition of Endonovo's assets and Intellectual Property (IP) for a minimum of $50 million. With completion of the APA, both Endonovo and SofPulse, Inc. share a strategic vision and a commitment for long term growth. Finalized Terms of SofPulse, Inc. Spi

  • GlobeNewswire

    Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions

    US Army Medical Research and Development Command Vendor Day Los Angeles, CA, March 04, 2024 (GLOBE NEWSWIRE) -- SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off company -- announced today the participation of its SofPulse® Pulsed Electro-Magnetic Field (PEMF) FDA-cleared medical device in the United States Army Medical Research and Development Command (USAMRDC) May 2024 Vendor Day. The USAMRDC is the Army's medical materiel developer, responsible for medical res

  • GlobeNewswire

    Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million

    Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the sale of the SofPulse® business and medical Intellectual Property (IP) to SofPulse, Inc.. ENDV is expected to receive the greater of $50 million or a price to be determined by a qualified third party's ass